<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02303158</url>
  </required_header>
  <id_info>
    <org_study_id>IISPV-LIDEAL-HTVC</org_study_id>
    <nct_id>NCT02303158</nct_id>
  </id_info>
  <brief_title>Relationship Between Protein Biomarkers in Cerebrospinal Fluid and Alzheimer&amp;Apos;s Disease in Patients With Depression</brief_title>
  <acronym>LIDEAL</acronym>
  <official_title>Study of the Relationship Between Protein Biomarkers in Cerebrospinal Fluid and the Risk of Progression to Alzheimer&amp;Apos;s Disease in a Cohort of Patients With Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Investigacio Sanitaria Pere Virgili</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Investigacio Sanitaria Pere Virgili</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is currently accepted that depression during midlife is a risk factor for Alzheimer's
      disease (AD). Furthermore, several prospective population studies have demonstrated that
      depression is an independent risk factor for incident dementia of different types (e.g.
      vascular, mixed, Alzheimer's disease). However, it is not clear, what are the mechanisms that
      link depression and dementia, and if depression can be a prodromal manifestation of AD. There
      are also studies that suggest that depression could be an initial sign of AD.

      Objective:

        1. Demonstrate that late life depression (over 60 years of age) constitutes the first
           manifestation of AD.

        2. Define by rating scales and life stressors have differential risk profiles evolutionary
           AD.

        3. To study the relationship between the subtypes of depression and CSF biomarkers,
           neurophycological test and evolution to AD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Groups of subjects: patients with recent apparition of late life depression without
      fulfilling the dementia criteria (Global Deterioration Scale, GDS, stages 1, 2 and 3). A
      longitudinal, prospective population study with two years follow-up. A cohort of will be
      included in the study. The patient's depression will be defined and categorized according to
      its severity (Yesavage Scale), whether it's endogenous or reactive (Holmes and Rahe scale)
      and taking into account the patient's medical history of depression.

      There will be a prospective follow-up of conversion to dementia (starting from GDS Stage 4).
      It will be considered that dementia corresponds to AD if the biological markers of LCR
      present typical changes of AD at the moment of inclusion (Beta amyloid low and P-tau high).

      It will be studied if there's any correlation between the clinically defined depression types
      and a high risk of progression to dementia and especially to AD.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of cerebrospinal fluid</measure>
    <time_frame>between the second and the fifth day after inclusion visit</time_frame>
    <description>Measure alterations in amyloid AB 1-42, total tau protein and phosphorylated tau protein, in pg/ml. Those alterations will be correlated with the evolution to dementia at final visit (after 24 months +/- 5 days)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Conversion to dementia</measure>
    <time_frame>first measure at inclusion visit and second measure at final visit (after 24 months +- 5 days).</time_frame>
    <description>Measure increases scores in Global Dementia Scale (GDS), considering no dementia GDS from 1 until 3, and evolution to dementia GDS form 3 until 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression subtypes</measure>
    <time_frame>at basal visit</time_frame>
    <description>classify the type of depression by scores in two scales. One of them is Yesavage with scores between 11-17 corresponding with &quot;low depression&quot; and scores between 18-30 with &quot;major depression&quot;. the second ones is Vital Stressors Scale of Holmes and Rahe which define adaptative depression as scores upper than 150 and non adaptative depression as scores between 0 and 150.
Subtype of depression will be correlated with posterior evolution to dementia at final visit (after 24 months +/- 5 days)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Alzheimer's Disease</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      cerebrospinal fluid (CSF), blood serum, blood plasma and whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients referred from Primary Care and Psychiatry, Neurology with
        consultations for specialist for cognitive impairment and / or depression who met the
        inclusion criteria of the study assessment.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;= 60 years.

          -  GDS (Reisberg Gobal Dementia Scale) of 2 to 3.

          -  Geriatric Depression Scale of Yesavage &gt;=12.

          -  History of previous depressive episodes resolved, but the emotional situation 15
             months before inclusion, necessarily have to be normal.

        Exclusion Criteria:

          -  Established dementia of any cause, or secondary degenerative dementia of any origin

          -  Primary diagnosis of cognitive impairment with psychiatric illness (schizophrenia ,
             bipolar disorder, personality disorders ... )

          -  Dual diagnosis of chronic depression, dysthymia more than 15 months duration, or major
             depression with psychotic or atypical symptoms

          -  Neuroimaging with significant chronic vascular involvement

          -  To take drugs with known side effects on cognition and it is suspected that the
             neuropsychological deficits.

          -  Moderate or severe sensory deprivation or functional illiteracy in the
             neuropsychological study can not be performed

          -  Neoplastic diseasesContraindication to performing a lumbar puncture
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Josep Zaragoza, MD</last_name>
    <phone>0034977519126</phone>
    <phone_ext>2126</phone_ext>
    <email>pzbhtvc@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Tortosa, Verge de la Cinta</name>
      <address>
        <city>Tortosa</city>
        <state>Tarragona</state>
        <zip>43500</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josep Zaragoza, MD</last_name>
      <phone>977519126</phone>
      <phone_ext>2126</phone_ext>
      <email>pzbhtvc@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Silvia Reverté, RN, BsC</last_name>
      <phone>977519126</phone>
      <phone_ext>2126</phone_ext>
      <email>neurociencies@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gerard Piñol, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sonia Escalante, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eva Forcadell, Nps</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sonia Galvez, Nps</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia Reverté, RN, BsC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patricia Esteve, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Tam CW, Lam LC. Association between late-onset depression and incident dementia in Chinese older persons. East Asian Arch Psychiatry. 2013 Dec;23(4):154-9.</citation>
    <PMID>24374487</PMID>
  </results_reference>
  <results_reference>
    <citation>Gracia-García P, de-la-Cámara C, Santabárbara J, Lopez-Anton R, Quintanilla MA, Ventura T, Marcos G, Campayo A, Saz P, Lyketsos C, Lobo A. Depression and incident Alzheimer disease: the impact of disease severity. Am J Geriatr Psychiatry. 2015 Feb;23(2):119-29. doi: 10.1016/j.jagp.2013.02.011. Epub 2013 Jun 20.</citation>
    <PMID>23791538</PMID>
  </results_reference>
  <results_reference>
    <citation>Diniz BS, Butters MA, Albert SM, Dew MA, Reynolds CF 3rd. Late-life depression and risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry. 2013 May;202(5):329-35. doi: 10.1192/bjp.bp.112.118307. Review.</citation>
    <PMID>23637108</PMID>
  </results_reference>
  <results_reference>
    <citation>Wallin K, Boström G, Kivipelto M, Gustafson Y. Risk factors for incident dementia in the very old. Int Psychogeriatr. 2013 Jul;25(7):1135-43. doi: 10.1017/S1041610213000409. Epub 2013 Apr 11.</citation>
    <PMID>23574921</PMID>
  </results_reference>
  <results_reference>
    <citation>Rosenberg PB, Mielke MM, Appleby BS, Oh ES, Geda YE, Lyketsos CG. The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease. Am J Geriatr Psychiatry. 2013 Jul;21(7):685-95. doi: 10.1016/j.jagp.2013.01.006. Epub 2013 Feb 6.</citation>
    <PMID>23567400</PMID>
  </results_reference>
  <results_reference>
    <citation>Nozaki S, Yoshimura K, Mimura M. [Depression and dementia: perspectives from clinical studies]. Brain Nerve. 2012 Dec;64(12):1387-97. Review. Japanese.</citation>
    <PMID>23209065</PMID>
  </results_reference>
  <results_reference>
    <citation>Potter GG, Wagner HR, Burke JR, Plassman BL, Welsh-Bohmer KA, Steffens DC. Neuropsychological predictors of dementia in late-life major depressive disorder. Am J Geriatr Psychiatry. 2013 Mar;21(3):297-306. doi: 10.1016/j.jagp.2012.12.009.</citation>
    <PMID>23395197</PMID>
  </results_reference>
  <results_reference>
    <citation>Gao Y, Huang C, Zhao K, Ma L, Qiu X, Zhang L, Xiu Y, Chen L, Lu W, Huang C, Tang Y, Xiao Q. Depression as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Int J Geriatr Psychiatry. 2013 May;28(5):441-9. doi: 10.1002/gps.3845. Epub 2012 Jul 19. Review. Retraction in: Int J Geriatr Psychiatry. 2015 Apr;30(4):435.</citation>
    <PMID>22815126</PMID>
  </results_reference>
  <results_reference>
    <citation>Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014 Jun;13(6):614-29. doi: 10.1016/S1474-4422(14)70090-0. Erratum in: Lancet Neurol. 2014 Aug;13(8):757.</citation>
    <PMID>24849862</PMID>
  </results_reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2014</study_first_submitted>
  <study_first_submitted_qc>November 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2014</study_first_posted>
  <last_update_submitted>November 23, 2015</last_update_submitted>
  <last_update_submitted_qc>November 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Depression</keyword>
  <keyword>dementia</keyword>
  <keyword>cerebrospinal fluid</keyword>
  <keyword>neuropsychological</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

